英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

dahlin    音标拼音: [d'ɑlɪn]
菊粉; 菊粉; 菊糖; 菊糖

菊粉; 菊粉; 菊糖; 菊糖

Inulin \In"u*lin\, n. [From NL. {Inula Helenium}, the
elecampane: cf. F. inuline.] (Chem.)
A substance of very wide occurrence. It is found dissolved in
the sap of the roots and rhizomes of many composite and other
plants, as {Inula}, {Helianthus}, {Campanula}, etc., and is
extracted by solution as a tasteless, white, semicrystalline
substance, resembling starch, with which it is isomeric,
having fructose units in place of most of the glucose units.
It is intermediate in nature between starch and sugar, and
replaces starch as the reserve food in Compositae. Called
also {dahlin}, {helenin}, {alantin}, {alant starch}, etc.
[1913 Webster PJC]


Dahlin \Dah"lin\ (d[aum]"l[i^]n), n. [From {Dahlia}.] (Chem.)
A variety of starch extracted from the dahlia; -- called also
{inulin}. See {Inulin}.
[1913 Webster]


请选择你想看的字典辞典：
单词字典翻译
Dahlin查看　Dahlin　在百度字典中的解释百度英翻中〔查看〕
Dahlin查看　Dahlin　在Google字典中的解释Google英翻中〔查看〕
Dahlin查看　Dahlin　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Cemiplimab-rwlc - NCI - National Cancer Institute
    FDA label information for this drug is available at DailyMed Use in Cancer Cemiplimab-rwlc is approved to treat adults with: Basal cell carcinoma (BCC) (a type of skin cancer) It is used in patients whose cancer has spread after treatment with hedgehog pathway inhibitor therapy or who cannot receive hedgehog pathway inhibitor therapy Cutaneous squamous cell carcinoma (a type of skin cancer
  • LIBTAYO® (cemiplimab-rwlc) | Official HCP Website
    LIBTAYO® (cemiplimab-rwlc) is a prescription medicine indicated for the treatment of adult patients with advanced NSCLC, CSCC, BCC, and as an adjuvant treatment for high-risk CSCC See Important Safety full Prescribing Information
  • LIBTAYO (cemiplimab-rwlc) Label - Food and Drug Administration
    LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation (1)
  • Libtayo (Cemiplimab-rwlc Injection): Side Effects, Uses . . .
    Drug Summary What Is Libtayo? Libtayo (cemiplimab -rwlc) is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation What Are Side Effects of Libtayo?
  • Libtayo (cemiplimab-rwlc) FDA Approval History - Drugs. com
    Libtayo (cemiplimab-rwlc) is a programmed death receptor-1 (PD-1) blocking antibody for the treatment of cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC), and non-small cell lung cancer (NSCLC)
  • Libtayo (cemiplimab-rwlc): Uses, Side Effects . . . - WebMD
    Libtayo (cemiplimab-rwlc) is commonly used to treat certain types of cancer It is used to treat certain types of skin cancers, including cutaneous squamous cell carcinoma (CSCC) and basal cell
  • label - Food and Drug Administration
    LIBTAYO in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is:
  • Cemiplimab (Libtayo Regeneron) - Guidelines+ Monographs
    Libtayo is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC), locally advanced or metastatic basal cell carcinoma (laBCC or mBCC), and non-small cell lung cancer (NSCLC) It was initially approved in 2018
  • Libtayo (cemiplimab) dosing, indications, interactions . . .
    Medscape - Cutaneous squamous cell carcinoma and basal cell carcinoma dosing for Libtayo (cemiplimab), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy lactation schedules, and cost information
  • Cemiplimab: Side Effects, Uses, Dosage, Interactions, Warnings
    Cemiplimab is a cancer medicine that helps your immune system fight certain cancers What it treats Advanced or hard-to-treat: Some skin cancers (certain squamous cell and basal cell skin cancers) Some types of lung cancer (non–small cell lung cancer) Cemiplimab is available under the following different brand names: Libtayo, cemiplimab-rwlc





中文字典-英文字典  2005-2009